ApoCell, Inc. Announces Delivery of First Prototypes of ApoStream™ Circulating Tumor Cell (CTC) Isolation Technology to National Cancer Institute
5/16/2013 9:14:32 AM
More...
|
Hadasit Bio Holdings Flagship Portfolio Company Enlivex Therapeutics Ltd. Awarded Orphan Drug Status for ApoCell, Inc. Treatment by the FDA
4/4/2013 10:18:21 AM
More...
|
ApoCell, Inc.'s Circulating Tumor Cell (CTC) Capture Technology First to Reliably Detect and Recover Deadly Liver Cancer Cells
4/3/2012 9:25:53 AM
More...
|
ApoCell, Inc. Awarded $2.9 Million from SAIC-Frederick, Inc. (SAI) to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program
8/10/2011 10:31:50 AM
More...
|
Summit Partners Invests in ApoCell, Inc., a Leading Innovative Cancer Diagnostics Company
9/30/2009 10:55:35 AM
More...
|
Summit Partners Invests in ApoCell, Inc., a Leading Innovative Cancer Diagnostics Company
9/30/2009 7:24:06 AM
More...
|
Reata Pharmaceuticals, Inc. Contracts ApoCell, Inc. to Detect Innovative Biomarkers in a Phase II Clinical Study of RTA 402 for Diabetic Renal Disease
6/10/2008 8:40:14 AM
More...
|
ApoCell, Inc. to Conduct Studies in Support of Novel Pfizer Inc. (PFE) Cancer Drug Trial
1/25/2008 8:55:42 AM
More...
|
ApoCell, Inc.'s Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6/8/2007 12:51:01 PM
More...
|